tbuckley/cabot-search huggingface dataset:
The Resource-Based Relative Value Scale: a methodological and policy evaluation
Authors: W. L. Roper
Journal: JAMA (1988)

The Resource-Based Relative Value Scale (RBRVS) developed by the research team at Harvard University is an important and ambitious effort. Dr Hsiao and his group are to be commended for their creative approach to this technically difficult and politically sensitive endeavor. My comments on the RBRVS study reflect my dual perspective as the administrator of the Health Care Financing Administration and as a pediatrician. First, I discuss the basic issues surrounding Medicare physician payment. Second, several of the important methodological aspects of the RBRVS study are reviewed. Finally, I discuss the likely impact of Medicare paying physicians according to fee schedules based on an RBRVS. <h3>Physician Payment Reform</h3> It is projected that in 1989 the Medicare program will spend more than $24 billion for physicians' services. Between 1975 and 1987, Medicare spending for physicians' services per beneficiary increased at a compound rate of 15% per year. About half of this
A phase III randomized, placebo-controlled, double-blind study of niraparib plus abiraterone acetate and prednisone versus abiraterone acetate and prednisone in patients with metastatic prostate cancer (NCT03748641).
Authors: Kim N. Chi, Dana E. Rathkopf, Gerhardt Attard, Matthew Raymond Smith, Eleni Efstathiou, David Olmos, Eric Jay Small, Ji Youl Lee, Paul R. Sieber, Curtis Dunshee, Deborah S. Ricci, Jason S. Simon, Xin Zhao, Nishi Kothari, Shinta Cheng, Shahneen Kaur Sandhu
Journal: Journal of Clinical Oncology (2020)

TPS257 Background: Preclinical data suggest synergistic antitumor activity when the PARP inhibitor (PARPi) niraparib is combined with the androgen pathway inhibitor abiraterone acetate. (1) The addition of a PARPi to abiraterone acetate plus prednisone (AAP) showed improved radiographic progression-free survival (rPFS) vs AAP alone in patients with mCRPC regardless of DNA repair gene defect (DRD) status. (2) Interim results from a phase 1 study support safety and tolerability of niraparib 200 mg combined with AAP in patients with mCRPC. (3) The objective of this Phase 3 study is to compare the efficacy and safety of niraparib plus AAP versus AAP with placebo as first-line therapy for mCRPC. Methods: This ongoing multicenter MAGNITUDE study will open in 300 sites across 28 countries and will enroll patients with mCRPC who have not received treatment in the metastatic castrate resistant setting other than ongoing androgen deprivation therapy [ADT] and ≤4 months of AAP. The DRD positive cohort (Cohort 1, n=400) will comprise patients whose tumors have DRD, as determined by a previously validated plasma or tissue assay. The cohort without DRD (Cohort 2, n=600) will enroll patients whose tumors are not found to have DRD. Enrollment began in February 2019. The primary objective of the study is to compare radiographic progression-free survival (rPFS) as assessed by blinded independent central radiology review for patients treated with niraparib and AAP versus placebo and AAP. To test superiority of the combination vs AAP, sample sizes were estimated to provide 92% power to detect HR≤0.65 rPFS in the DRD positive cohort and 94% power to detect HR≤0.67 in rPFS in the cohort without DRD, both at a 2-tailed level of significance of 0.05. The main secondary objectives are time to symptomatic progression, time to cytotoxic chemotherapy, and overall survival. Safety and pharmacokinetic profiles will be evaluated.1) Rajendra N, et al. Cancer Res 2019;79 (13 Suppl): Abstract nr 2134. 2) Clarke N, et al. Lancet Oncol. 2018;(7):975-986. 3) Saad, et al. Ann Oncol, 2018;29 (suppl 8), mdy284.043, https://doi.org/10.1093/annonc/mdy284.043 ). Clinical trial information: NCT03748641.
AB0257 Clinical Outcome of 2 Years Treatment of The Early Phase Rheumatoid Arthritis
Authors: Y. Sugimura, S. Miyamoto, T. Kashiwagura, M. Kobayashi, N. Miyakoshi, Y. Shimada
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Few studies have reported long term clinical outcome of patients with early phase rheumatoid arthritis (RA). <h3>Objectives</h3> The objectives of this study were to investigate outcome of 2 years treatment for RA which was started less than 12 months after RA symptoms first appeared and to evaluate prediction factors of poorly controlled patients at 2 years. <h3>Methods</h3> From a total of 1663 RA patients registered in the Akita Orthopedic Group on Rheumatoid Arthritis (AORA) in 2012, 66 patients were treated within the first year of RA appearance, and enrolled in this study. Sex, age, RA disease duration, Steinbroker9s stage, Steinbroker9s class, medications and DAS28-CRP at the baseline and 2 years post-treatment were evaluated. Furthermore, we compared the group of remission (REM) or low disease activity (LDA) with the group of medium disease activity (MDA) or high disease activity (HDA) at 2 years. <h3>Results</h3> At the baseline, the patients included 13 males and 53 females. Mean age and RA disease duration were 59 (21–85) years and 7 (1–11) months, respectively. Fifty-four, 8, 4 and 0 patients were classified into Steinbroker9s stage I, II, III, and IV, respectively. Thirty-nine, 25, 2 and 0 patients were classified into Steinbroker9s class I, II, III, and IV, respectively. Thirty-seven (56%), 24 (36%), and 16 (24%) patients were treated with MTX, DMARDs, and PSL, respectively. In DAS28-CRP, 19 (29%), 13 (20%), 32 (48%), and 2 (3%) patients showed REM, LDA, MDA, and HDA, respectively. Forty-four patients were followed-up for 2 years. At 2 years, 30, 7, 5, and 2 patients were classified into Steinbroker9s stage I, II, III, and IV, respectively. Thirty-one, 12, 1, and 0 patients are classified into Steinbroker9s class I, II, III, and IV, respectively. In DAS28-CRP, 33 (75%), 4 (9%), 7 (16%), and 0 (0%) patients showed REM, LDA, MDA, and HDA, respectively. Compared with the group of REM or LDA, the group of MDA or HDA had significantly older age (P=0.018), higher Steinbroker9s stage (P=0.012) and higher DAS28-CRP (P=0.049) at the baseline. <h3>Conclusions</h3> At 2 years, 75% of patients with early phase RA achieved REM. Older age, higher Steinbroker9s stage and higher DAS28-CRP at the baseline could be prediction factors of poorly controlled patients at 2 years. <h3>Acknowledgement</h3> We wish to thank the members of AORA. <h3>Disclosure of Interest</h3> None declared
Fabricius ab Aquapendente (1537-1619) preceptor of Harvey
Journal: JAMA (1966)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
PHTHISIOPHOBIA.
Journal: JAMA (1902)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Erratum: Live attenuated, multiply deleted simian immunodeficiency virus causes AIDS in infant and adult macaques
Authors: T.W. Baba, V. Liska, A.H. Khimani, N.B. Ray, P.J. Dailey, D. Penninck, R. Bronson, M.F. Greene, H.M. McClure, L.N. Martin, R.M. Ruprecht
Journal: Nature Medicine (1999)
THE ALLEGED ANTIMALARIAL INFLUENCE OF LIME.
Journal: JAMA (1900)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Phase Ib/II study of neoadjuvant chemoradiotherapy with CRLX101 and capecitabine for locally advanced rectal cancer.
Authors: Andrew Wang, Autumn Jackson McRee, A. William Blackstock, Bert H. O'Neil, Dominic T. Moore, Benjamin F. Calvo, Michael Sangmin Lee, Curran Murphy, Kim Caliri, Maureen T. Tynan, Adrian Mario Senderowicz, Joel E. Tepper, Hanna Kelly Sanoff
Journal: Journal of Clinical Oncology (2017)

e15144 Background: There is strong interest in the development of novel agents to further improve the therapeutic ratio of neoadjuvant chemoradiotherapy for rectal cancer. CRLX101 is an investigational nanoparticle-drug conjugate with a camptothecin payload. The purpose of this Phase Ib/II study is to assess toxicity and to evaluate whether the addition of CRLX101 to chemoradiotherapy can improve pathologic complete response (pCR) for rectal cancer. Methods: This is a single-arm multicenter Phase Ib/II study examining the addition of CRLX101 to a standard capecitabine-based chemoradiotherapy regimen. Phase Ib employs a 3+3 dose escalation design with starting dose of 12 mg/m 2 every other week (QOW). Dose level +1 was 15 mg/m 2 (MTD for CRLX101 single agent QOW). Upon reaching MTD for QOW dosing, protocol was modified to evaluate QW CRLX101 dosing starting at 12 mg/m 2 and 15 mg/m 2 as +1 level. Secondary endpoints included pCR and clinical outcome. Results: A total of 32 patients were enrolled on the trial. 26/32 had T3-4, 9/32 had N2 and 16/32 had N1 disease. For QOW dosing, 9 patients completed treatment without DLT and MTD was identified as 15 mg/m 2 QOW. 14 patients were treated on the Phase II portion of the study at 15 mg/m 2 QOW prior to the initiation of weekly dosing Phase Ib cohorts. For QW dosing, 0/3 patients experienced DLT at 12 mg/m 2 and 1/6 patients experienced DLT at 15 mg/m 2 . The DLT was skin desquamation requiring treatment delay. QW MTD was identified as 15 mg/m 2 . Toxicities (all grade 3 except lymphopenia) that could possibly be attributed to CRLX101 are in Table 1. Full clinical and pathologic staging were available for 29/32 patients. Mean neoadjuvant rectal (NAR) score was 19 with standard deviation of 15. At the weekly MTD, 3/6 patients had pCR. Conclusions: CRLX101 weekly at 15 mg/m 2 + standard capecitabine-based chemoradiotherapy appears to be well tolerated, with promising pCR rates that warrants further evaluation. A larger PhII trial should be considered with this regimen. Clinical trial information: NCT02010567. [Table: see text]
Resolution of postvagotomy dysphagia
Authors: S. L. Carter
Journal: JAMA (1978)

A PATIENT with severe dysphagia following vagotomy and antrectomy led me to review the literature concerning the frequency, cause, and treatment of postvagotomy dysphagia. The patient described illustrates the difficulty encountered in this rare complication and also demonstrates the satisfactory results obtained with conservative management. <h3>Report of a Case</h3> A 32-year-old woman had a year's history of duodenal ulcer confirmed by gastrointestinal (GI) tract roentgenograms and endoscopy. Her gastric analysis showed a basal acid output of 2.1 mEq/hr and a maximum stimulated output of 17.4 mEq/hr. Because of the failure of her medical treatment, she underwent vagotomy and antrectomy with a Billroth II anastomosis. She had an unremarkable postoperative course except for a wound hematoma, possibly due to prophylactic therapy with subcutaneous heparin sodium, 5,000 units every 12 hours. She left the hospital one week postoperatively able to eat soft foods. However, she returned three days after discharge, vomiting, stating
Journal of Chronic Diseases, St. Louis
Journal: JAMA (1964)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Ueber die Dekompensation der erworbenen Herzklappenfehler und ihre Behandlung.
Journal: JAMA (1930)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The Cover
Authors: M. THERESE SOUTHGATE
Journal: JAMA (1982)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Tutorial and Workshop in the Use of Immunocytochemistry and Electron Microscopy in Tumor Diagnosis
Journal: JNCI Journal of the National Cancer Institute (1985)

Tutorial and Workshop in the Use of Immunocytochemistry and Electron Microscopy in Tumor Diagnosis Get access JNCI: Journal of the National Cancer Institute, Volume 75, Issue 1, July 1985, Page 183, https://doi.org/10.1093/jnci/75.1.183-d Published: 01 July 1985
Frida Kahlo
Authors: Carmen Pinto
Journal: BMJ (2005)

An exhibition at Tate Modern, Bankside, London SE1, until 9 October www.tate.org.uk/modern/exhibitions/kahlo/ Rating: ![Graphic][1]</img>![Graphic][2]</img>![Graphic][3]</img>![Graphic][4]</img> T he Mexican painter Frida Kahlo (1907-54) is well known through her self portraits, which defiantly integrate the personal and the political. In recent years she has become an iconic figure, a “film star,” a tourist attraction. Kahlo grew up in a mix of cultures, having a catholic mother of Spanish and Mexican Indian origin and a German father, and during the Mexican Revolution she embraced the national pride in indigenous arts and traditions. Her life is closely related to medicine for a number of reasons. At the age of … [1]: /embed/inline-graphic-1.gif [2]: /embed/inline-graphic-2.gif [3]: /embed/inline-graphic-3.gif [4]: /embed/inline-graphic-4.gif
ETHER INTOXICATION.
Journal: JAMA (1890)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Response of bladder and urethral mucosa to catheterization
Authors: R. U. Anderson
Journal: JAMA (1979)

Short-term urinary bladder drainage with the use of urethral Foley catheters is practiced frequently in hospitals throughout the country. We studied the urethral and bladder cellular proliferation after exposure to latex, silicone-coated latex, and 100% silicone catheters. Fifty-one male patients were studied; no differences in acute cellular reaction could be detected among the three different catheter materials. Promotion of all-silicone products in hospital use may be unwarranted. (<i>JAMA</i>242:451-453, 1979)
Fiftieth Anniversary of the Hartford Medical Society
Journal: JAMA (1898)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
IS MEDICINE ATTRACTIVE TO SCHOLARLY MEN?
Journal: JAMA (1903)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal